Alzheimer’s drug granted accelerated approval by FDA. These are the risks

CNN’s Sanjay Gupta reports the US Food and Drug Administration granted accelerated approval for the Alzheimer’s disease drug Lecanemab, one of the first experimental dementia drugs to appear to slow the progression of cognitive decline.